5J0D

Crystal structure of the bromodomain of human CREBBP in complex with a benzoxazepine compound

5J0D の概要

• エントリーDOI: 10.2210/pdb5j0d/pdb
• 分子名称: CREB-binding protein, 7-(3,5-dimethoxyphenyl)-N-[(3S)-1-methylpiperidin-3-yl]-4-propanoyl-2,3,4,5-tetrahydro-1,4-benzoxazepine-9-carboxamide, 1,2-ETHANEDIOL, ... (4 entities in total)
• 機能のキーワード: transcription, histone acetyl transferase activity, structural genomics, structural genomics consortium, sgc
• 由来する生物種: Homo sapiens (Human)
• 細胞内の位置: Cytoplasm: Q92793
• タンパク質・核酸の鎖数: 1
• 化学式量合計: 14891.14

構造登録者

Tallant, C.,Popp, T.A.,Fedorov, O.,Siejka, P.,Picaud, S.,von Delft, F.,Arrowsmith, C.H.,Edwards, A.M.,Bountra, C.,Bracher, F.,Knapp, S.,Structural Genomics Consortium (SGC) (登録日: 2016-03-28, 公開日: 2016-10-05, 最終更新日: 2024-01-10)

主引用文献

Popp, T.A.,Tallant, C.,Rogers, C.,Fedorov, O.,Brennan, P.E.,Muller, S.,Knapp, S.,Bracher, F.
Development of Selective CBP/P300 Benzoxazepine Bromodomain Inhibitors.
J.Med.Chem., 59:8889-8912, 2016

PubMed Abstract: CBP (CREB (cAMP responsive element binding protein) binding protein (CREBBP)) and P300 (adenovirus E1A-associated 300 kDa protein) are two closely related histone acetyltransferases (HATs) that play a key role in the regulation of gene transcription. Both proteins contain a bromodomain flanking the HAT catalytic domain that is important for the targeting of CBP/P300 to chromatin and which offeres an opportunity for the development of protein-protein interaction inhibitors. Here we present the development of CBP/P300 bromodomain inhibitors with 2,3,4,5-tetrahydro-1,4-benzoxazepine backbone, an N-acetyl-lysine mimetic scaffold that led to the recent development of the chemical probe I-CBP112. We present comprehensive SAR of this inhibitor class as well as demonstration of cellular on target activity of the most potent and selective inhibitor TPOP146, which showed 134 nM affinity for CBP with excellent selectivity over other bromodomains.

PubMed: 27673482
DOI: 10.1021/acs.jmedchem.6b00774

実験手法

X-RAY DIFFRACTION (1.05 Å)